In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), with a price target of $84.00.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors, primarily the promising growth prospects of Tarsus Pharmaceuticals. One of the key reasons is the positive feedback from key opinion leaders (KOLs) regarding the effectiveness and tolerability of Xdemvy, a treatment for Demodex blepharitis. Despite some initial challenges with insurance coverage, improvements have been noted, which could enhance early adoption and usage of the product.
Moreover, the recent high-profile advertising campaigns, such as those aired during major NFL games, are expected to increase patient awareness and demand, potentially driving further growth. Additionally, prescribers are considering Xdemvy for other related conditions, which could broaden its market reach. Overall, these factors suggest a strong potential for continued growth in the coming years, supporting the Buy recommendation.
Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Larimar Therapeutics, and Tarsus Pharmaceuticals. According to TipRanks, Jubinville, PhD has an average return of 3.3% and a 40.32% success rate on recommended stocks.
In another report released on January 27, Barclays also maintained a Buy rating on the stock with a $62.00 price target.